The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

16 articles for NP Walker


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11 beta-HSD1 inhibitors.EBI
Amgen
Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.EBI
Amgen
Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.EBI
Amgen
Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.EBI
Amgen
Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ).EBI
Arcus Biosciences
SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase.EBI
Amgen
Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.EBI
Arcus Biosciences
Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors.EBI
Arcus Biosciences
Discovery of Potent and Selective PI3Kγ Inhibitors.EBI
Arcus Biosciences
Discovery of AB680: A Potent and Selective Inhibitor of CD73.EBI
Arcus Biosciences
Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.EBI
Arcus Biosciences
Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4.EBI
Amgen
Therapeutic compounds, compositions and methods of use thereofBDB
Genentech
1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitorsBDB
H. Lundbeck
3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infectionBDB
Hoffmann-La Roche
Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.BDB
National Taiwan University